SECsense Logo

Dexcom, Inc. 8-K/A Report: Key Amendments and Updates for Investors

$DXCM
Form 8-K/A
Filed on: 2025-05-09
Source
Dexcom, Inc. 8-K/A Report: Key Amendments and Updates for Investors

Based on the provided section of the financial report, here are the key insights extracted:

  1. Entity Information:
  • Company Name: Dexcom, Inc.
  • State of Incorporation: Delaware (DE)
  • CIK: 0001093557
  • Address: 6340 Sequence Drive, San Diego, CA 92121
  • Phone Number: 858-200-0200
  1. Filing Details:
  • Filing Type: 8-K/A (Amendment to a current report)
  • Filing Date: March 6, 2025
  • SEC File Number: 000-51222
  • Securities Registration Number: 33-0857544
  1. Stock Information:
  • Common Stock Par Value: $0.001 per share
  • Ticker Symbol: DXCM
  • Exchange: NASDAQ
  1. Reporting Period:
  • Report Date: March 6, 2025 (the same as the filing date)

Summary Insights:

  • This report is an amendment (8-K/A) from Dexcom, Inc., indicating that the company is making updates or corrections to previously filed information as of March 6, 2025.
  • The company operates in the healthcare technology sector, specifically focusing on diabetes management solutions, which is implied by its name.
  • The report is filed with the SEC, suggesting regulatory compliance and the need to provide timely updates to shareholders and the market.
  • Dexcom is publicly traded on NASDAQ under the ticker DXCM, indicating its status as a publicly held corporation.

This information may be important for investors and analysts tracking the company’s performance or any significant events that could affect its stock price or operations.